Equities

Design Therapeutics Inc

DSGN:NSQ

Design Therapeutics Inc

Actions
  • Price (USD)5.83
  • Today's Change0.04 / 0.69%
  • Shares traded161.25k
  • 1 Year change+185.78%
  • Beta1.8520
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.

  • Revenue in USD (TTM)0.00
  • Net income in USD-50.53m
  • Incorporated2017
  • Employees57.00
  • Location
    Design Therapeutics Inc6005 Hidden Valley Road, Suite 110CARLSBAD 92011United StatesUSA
  • Phone+1 (858) 293-4900
  • Fax+1 (302) 636-5454
  • Websitehttps://www.designtx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vanda Pharmaceuticals Inc.190.86m-16.39m302.52m203.00--0.559--1.59-0.2824-0.28243.299.290.29679.305.30940,187.20-2.556.61-2.957.6293.6290.55-8.5915.184.84----0.00-24.27-0.0496-60.02-36.96-56.77--
Tscan Therapeutics Inc12.20m-104.41m306.19m175.00--1.20--25.10-1.05-1.050.12254.820.0353----79,220.78-30.19---33.78-------855.84------0.1066--55.52---34.73------
Taysha Gene Therapies Inc12.87m-114.34m307.41m52.00--2.77--23.88-0.8987-0.89870.06430.54060.0913----247,557.70-81.11---116.01-------888.18------0.2598--517.55--32.80------
AVITA Medical Inc60.04m-57.32m310.58m207.00--25.62--5.17-2.23-2.232.330.46640.74091.537.30290,048.30-70.74---86.14--86.46---95.47--3.37-11.270.7768--45.68---32.69------
Nautilus Biotechnology Inc0.00-70.21m312.65m161.00--1.40-----0.561-0.5610.001.780.00----0.00-24.29---25.05--------------0.00-------9.93------
Mersana Therapeutics Inc29.94m-104.77m315.27m123.00--37.41--10.53-0.8648-0.86480.24690.06870.1222--38.14243,390.30-42.75-61.68-59.36-81.35-----349.98-622.19----0.7508--38.6528.3215.94--9.61--
AC Immune SA17.69m-69.13m316.61m133.00--2.25--17.89-0.7332-0.73320.19111.420.0787--28.76133,041.40-30.73-18.25-42.90-19.52-----390.68-148.29---128.010.0255--276.1415.5223.35---15.49--
Tango Therapeutics Inc43.38m-123.40m316.88m140.00--1.38--7.30-1.15-1.150.40412.130.1112----309,885.70-31.62---35.28-------284.43------0.00--46.93--5.95------
Artiva Biotherapeutics Inc-100.00bn-100.00bn318.40m82.00--------------1.09----------------------------0.0087--579.21--51.15------
Rezolute Inc0.00-68.46m323.32m59.00--2.46-----1.33-1.330.002.270.00----0.00-53.39-50.36-56.66-53.25------------0.00-------32.19------
Aldeyra Therapeutics Inc0.00-37.87m328.01m10.00--3.34-----0.6387-0.63870.001.650.00----0.00-26.89-36.79-31.76-40.77------------0.1342------39.47------
Design Therapeutics Inc0.00-50.53m330.10m57.00--1.26-----0.8982-0.89820.004.610.00----0.00-17.39---17.96--------------0.00-------5.61------
Codexis Inc64.45m-62.09m332.02m174.00--4.52--5.15-0.878-0.8780.91490.9020.42597.033.62370,379.30-41.03-17.13-54.21-20.2375.9677.29-96.35-37.043.15--0.2806---49.392.97-126.96--9.80--
iTeos Therapeutics Inc35.00m-108.14m338.56m157.00--0.51--9.67-3.00-3.000.951718.180.0481--1.52222,929.90-14.865.84-15.557.02-----308.9622.09----0.000.00-95.29---216.54--68.45--
enGene Holdings Inc0.00-123.44m349.30m33.00--1.52-----4.77-4.770.005.210.00----0.00-78.13---84.20-------------3.140.0906-------260.87------
Lyell Immunopharma Inc54.00k-210.26m358.79m224.00--0.5512--6,644.33-0.8297-0.82970.00022.210.00007----241.07-28.23---29.53-------389,368.50------0.00---99.85---28.13------
Data as of Nov 08 2024. Currency figures normalised to Design Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

26.37%Per cent of shares held by top holders
HolderShares% Held
Logos Global Management LPas of 09 Aug 20244.22m7.45%
BlackRock Fund Advisorsas of 30 Jun 20242.01m3.54%
Baker Bros. Advisors LPas of 30 Jun 20241.70m2.99%
Tang Capital Management LLCas of 30 Jun 20241.48m2.62%
The Vanguard Group, Inc.as of 30 Jun 20241.27m2.24%
Almitas Capital LLCas of 30 Jun 20241.25m2.21%
Point72 Asset Management LPas of 30 Jun 2024992.09k1.75%
Geode Capital Management LLCas of 30 Jun 2024707.97k1.25%
SSgA Funds Management, Inc.as of 30 Jun 2024695.42k1.23%
Millennium Management LLCas of 30 Jun 2024610.80k1.08%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.